Antidepressants for the new millennium
by
Skolnick P
Neuroscience Discovery, Eli Lilly,
Lilly Corporate Center, Indianapolis, IN 46285, USA.
skolnick_phil@lilly.com
Eur J Pharmacol 1999 Jun 30; 375(1-3):31-40

ABSTRACT

Despite a remarkable structural diversity, most conventional antidepressants may be viewed as 'monoamine based', increasing the synaptic availability of serotonin, norepinephrine, and/or dopamine. Both preclinical and recent clinical studies indicate that compounds which reduce transmission at N-methyl-D-aspartate (NMDA) receptors are antidepressant. Moreover, chronic administration of antidepressants to mice alters both the mRNA levels encoding N-methyl-D-aspartate receptor subunits and radioligand binding to these receptors within circumscribed areas of the central nervous system. It is hypothesized that these two different treatment strategies converge to produce an identical functional endpoint: a region-specific dampening of NMDA receptor function. The pathways leading to this convergence provide a rudimentary framework for discovering novel antidepressants.

NMDA
Riluzole
Serotonin
Dopamine
Memantine
Monoamines
21st Century
Noradrenaline
Neurotrophins
NMDA antagonists
New antidepressants
Glutamate and GABA
Glutamate and depression
Glutamate and mood disorders
Are antidepressants neuroprotective?

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family